The Conversation (0)
ANGLE plc announced the Center for Women’s Health Tuebingen presented the first report on a successful establishment of a protocol for detecting disseminated tumor cells using cancer patient bone marrow with the Parsortix system.
ANGLE plc (OTCQX:ANPCY) announced the Center for Women’s Health Tuebingen presented the first report on a successful establishment of a protocol for detecting disseminated tumor cells (DTCs) using cancer patient bone marrow with the Parsortix system.
As quoted in the press release:
The reactivation of dormant DTCs and their release into the bloodstream as circulating tumor cells (CTCs), is the process by which a patient may, sometimes after many years of remission, suffer a relapse through metastasis. There is intense interest in the existence and status of such DTCs that are “hibernating” in the bone marrow.
At present, the method of choice for detecting DTCs is a density gradient centrifugation of the bone marrow to enrich for mononuclear cells and then an antibody-based staining for various cell markers. In experiments with spiked cancer cells, this procedure was shown to be accompanied by a tremendous reduction of target cells with an average of up to 80% cell loss. This may well be one reason why, in primary breast cancer, DTCs have been found in the bone marrow of only 20-30% of patients.
Click here to read the full press release.
Source: www.marketwired.com